Skip to Main Content

For archived live coverage of the hearing of the FDA’s advisory panel, click here.

By a narrow margin, an independent panel of advisers to the Food and Drug Administration on Wednesday decided that data from a single trial of an experimental drug developed by Amylyx Pharmaceuticals were not sufficient to conclude the therapy was an effective treatment against ALS.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment